Investigational small-molecule pan-ERR agonist (ERRα/β/γ) developed in the Burris laboratory, studied in animal models as an "exercise mimetic" for mitochondrial function, fat oxidation, and endurance capacity.
Last Updated: July 2026
SLU-PP-332 (also designated SR9861) is a synthetic small-molecule pan-agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ, most potent at ERRα (EC₅₀ ≈ 98 nM). It is not a peptide — chemically it is a naphthalene–hydrazone small molecule (C18H14N2O2, 290.32 g/mol) — and despite being marketed by many vendors as an "exercise-mimetic peptide," it has never been administered to humans in a controlled study. All published efficacy data come from rodent models. SLU-PP-332 is not approved by the FDA or any other regulator for any indication and is supplied strictly for research use only. The lab test table and shop directory above show Peptigrity's independent verification data, updated continuously as new HPLC tests are submitted.
SLU-PP-332 is the most widely used chemical probe for activating the estrogen-related receptors (ERRα/β/γ) — the transcription factors that coordinate mitochondrial biogenesis and the gene programs the body normally switches on during aerobic exercise. ERRs are orphan nuclear receptors: despite the name, they are not regulated by estrogen (the name reflects sequence homology to the estrogen receptor, nothing more). In skeletal-muscle models, SLU-PP-332 upregulates genes such as DDIT4 and amplifies mitochondrial function, cellular respiration, and fatty-acid oxidation — the pharmacological basis for the "exercise mimetic" hypothesis. Mechanistically this is a completely different lever from the GLP-1 class: semaglutide and tirzepatide act on appetite and insulin signaling, whereas SLU-PP-332 targets energy-expenditure transcription directly, with ERRα as the primary target.
The foundational evidence is a 2023 ACS Chemical Biology study from the Burris laboratory showing SLU-PP-332 triggered an ERRα-dependent acute aerobic-exercise-like response and enhanced exercise capacity in mice — with no human data before or since. Related rodent work reported reduced fat mass and improved metabolic parameters in diet-induced obese mice, attributed to increased fatty-acid oxidation and mitochondrial output. Evidence level: Preclinical (rodent) only. There are no human clinical trials, no human pharmacokinetics, and no human safety data of any kind. Oral bioavailability has additionally been reported as poor in research settings — a relevant caveat given that much of what is sold online is packaged as oral tablets or capsules, a route with no established absorption profile for this compound.
No — SLU-PP-332 is a synthetic small molecule (a naphthalene-hydrazone; C18H14N2O2, 290.32 g/mol), not a peptide. The "peptide" label used across much of the research market is inaccurate. It is listed on Peptigrity because it is sold within the same research-compound ecosystem and shares the metabolic-research use case. Because it is a small molecule, the relevant purity signals are HPLC purity and mass-spectrometry identity confirmation against an expected molecular weight of 290.32 Da — the same verification logic we apply to peptides, on different chemistry.
Because SLU-PP-332 has never been given to humans in a controlled study, there is no established human side-effect profile, no known safe dose, and no long-term safety data. ERRs are broadly expressed across the heart, skeletal muscle, brain, and liver, so systemic ERR activation carries a theoretical risk of off-target effects that has simply not been characterized in people. For anyone evaluating this compound, the complete absence of human safety data is itself the primary risk to weigh. Evidence level: No human data. Country-specific import and legal considerations are covered in our peptide regulatory status by country guide.
SLU-PP-332 is not approved for human use anywhere in the world, and it has no active clinical-development program of the kind that leads to regulatory approval. It exists as a research chemical and chemical probe sold by laboratory-reagent suppliers and gray-market vendors, with no prescription pathway and research-use-only status. Buyers are responsible for verifying local rules — see the regulatory status by country guide.
With no reference product, no pharmacopeial standard, and a white powder most buyers cannot distinguish from filler, independent HPLC and mass-spec testing are the only objective signals that a vial contains what the label claims. The compound is sold as capsules, tablets, and lyophilized powder, and the incentive to underdose or mislabel is high in an unregulated market. Expected identity on analysis: C18H14N2O2, 290.32 Da. Learn how to read these results in our how-to-test-peptides hub and the reading peptide lab test results guide.
Peptigrity purchases SLU-PP-332 anonymously at standard customer pricing, sends it to independent ISO-accredited labs for HPLC and mass-spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above shows the full cross-shop dataset, sortable by date, purity, and labeled-vs-tested quantity. Our trust score weights independent lab purity and community reviews equally (50/50); the full methodology is documented in how we calculate trust scores.
This section is for educational and informational purposes only and does not constitute medical advice. SLU-PP-332 is an investigational compound not approved by the FDA or any other regulator for human use, and it has not been tested in humans. Always consult a qualified healthcare provider before using any research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.